KUALA LUMPUR, 24 SEPTEMBER 2020 – Ho Wah Genting Berhad’s (“HWGB” or the “Company”) (Bursa Stock Code:9601) wholly-owned subsidiary, HWGB Biotech Sdn Bhd (“HWGB Biotech”) [formerly known as HWG Consortium Sdn Bhd]’s, JV Partner, E-Mo Biology Inc (“EBI”) is collaborating with a US-based lab facility to develop and produce companion diagnostic systems. These systems, which utilises ELISA (enzyme-linked immunosorbent assay) and Western Blot methodology for the detection and qualification of RNA directed RNA polymerase (“RDRP”) IgG and IgA antibodies in human specimen against SARS-CoV-2 antigens.
Spokesperson of HWGB, Dr. Yaman Walid Kassab expressed: “We are encouraged by the progress made with the clinical study programme undertaken in our joint venture with EBI going into the potential COVID-19 preventive vaccine and now EBI is looking at companion diagnostic systems”.
“The research team is working very hard to ensure positive outcomes from the clinical study and we are monitoring every step of the way as we fully understand the impact of the on-going COVID-19 pandemic on people’s lives and livelihoods”.
To recap, HWGB Biotech had signed an agreement in August 2020 to collaborate with EBI in developing a COVID-19 preventive vaccine through phase IV clinical trials based on the use of the polio vaccine. The collaboration involves research and development, testing, registration, manufacturing and commercialisation of five provisional patent applications. The US Food and Drug Administration has responded twice to EBI’s application by requesting for further information on the clinical study.
HWGB Biotech has also submitted the necessary documentation to Malaysia’s National Medical Research Register on the use of the polio vaccine for the potential new indication, with the principal investigator for the research protocol being Dato’ Dr. Lai Kwong Choy and co-investigator Dr. Yaman Walid Kassab.
ABOUT HO WAH GENTING BERHAD
Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in Health Supplement, Biotechnology and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wire and cable and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wire and cable; and travel agent and tour related services.
For more information about HWGB Biotech, please visit https://hwgbbiotech.com/ and/or https://www.facebook.com/hwgbbiotech Please also feel free to subscribe to our newsletter online to get latest exciting developments of our new ventures. Click on http://subscription.hwgbbiotech.com to subscribe.